Patents by Inventor Andrew Huntington

Andrew Huntington has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY
    Publication number: 20230129181
    Abstract: The invention relates to specified benzamide compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of ?1-antitrypsin (A1AT), and may be used in the treatment of a disease or disorder such as ?1-antitrypsin deficiency (A1AD or AATD).
    Type: Application
    Filed: June 13, 2022
    Publication date: April 27, 2023
    Inventors: Nigel RAMSDEN, David John FOX, James Andrew HUNTINGTON, James Michael TOMLINSON
  • COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY
    Publication number: 20230102488
    Abstract: The invention relates to specified benzamide compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of ?1-antitrypsin (A1AT), and may be used in the treatment of a disease or disorder such as ?1-antitrypsin deficiency (A1AD or AATD).
    Type: Application
    Filed: June 13, 2022
    Publication date: March 30, 2023
    Inventors: Nigel RAMSDEN, David John FOX, James Andrew HUNTINGTON, James Michael TOMLINSON
  • COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY
    Publication number: 20230096524
    Abstract: The invention relates to specified benzamide compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of ?1-antitrypsin (A1AT), and may be used in the treatment of a disease or disorder such as ?1-antitrypsin deficiency (A1AD or AATD).
    Type: Application
    Filed: June 13, 2022
    Publication date: March 30, 2023
    Inventors: Nigel RAMSDEN, David John FOX, James Andrew HUNTINGTON, James Michael TOMLINSON
  • COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY
    Publication number: 20230093755
    Abstract: The invention relates to specified oxazole compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of ?1-antitrypsin (A1AT), and may be used in the treatment of a disease or disorder such as ?1-antitrypsin deficiency (A1AD or AATD).
    Type: Application
    Filed: June 13, 2022
    Publication date: March 23, 2023
    Inventors: Nigel RAMSDEN, David John FOX, James Andrew HUNTINGTON, James Michael TOMLINSON
  • COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY
    Publication number: 20230089087
    Abstract: The invention relates to specified carboxylic acid compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of ?1-antitrypsin (A1AT) and may be used in the treatment of a disease or disorder such as ?1-antitrypsin deficiency (A1AD or AATD).
    Type: Application
    Filed: June 13, 2022
    Publication date: March 23, 2023
    Inventors: Nigel RAMSDEN, David John FOX, James Andrew HUNTINGTON, James Michael TOMLINSON
  • COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY
    Publication number: 20220274932
    Abstract: The invention relates to oxopyrimidinyl-methyl-benzamide derivatives, for example in a pharmaceutically acceptable salt form or crystal form, pharmaceutical compositions comprising the derivatives, and their medical use, in particular for use in the treatment of ?1-antitrypsin deficiency (A1AD or AATD).
    Type: Application
    Filed: March 21, 2022
    Publication date: September 1, 2022
    Inventors: Nigel RAMSDEN, David John FOX, James Andrew HUNTINGTON
  • Compounds and their use for the treatment of alpha1-antitrypsin deficiency
    Patent number: 11312689
    Abstract: The invention relates to oxopyrimidinyl-methyl-benzamide derivatives, for example in a pharmaceutically acceptable salt form or crystal form, pharmaceutical compositions comprising the derivatives, and their medical use, in particular for use in the treatment of ?1-antitrypsin deficiency (A1AD or AATD).
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: April 26, 2022
    Assignee: Z FACTOR LIMITED
    Inventors: Nigel Ramsden, David John Fox, James Andrew Huntington
  • Thrombin-Binding Antibody Molecules And Uses Thereof
    Publication number: 20210371543
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Application
    Filed: June 10, 2021
    Publication date: December 2, 2021
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY
    Publication number: 20210332015
    Abstract: The invention relates to oxopyrimidinyl-methyl-benzamide derivatives, for example in a pharmaceutically acceptable salt form or crystal form, pharmaceutical compositions comprising the derivatives, and their medical use, in particular for use in the treatment of ?1-antitrypsin deficiency (A1AD or AATD).
    Type: Application
    Filed: June 11, 2021
    Publication date: October 28, 2021
    Inventors: Nigel RAMSDEN, David John FOX, James Andrew HUNTINGTON
  • Thrombin-binding antibody molecules and uses thereof
    Patent number: 11155637
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: October 26, 2021
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Thrombin-Binding Antibody Molecules And Uses Thereof
    Publication number: 20200002435
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Application
    Filed: June 26, 2019
    Publication date: January 2, 2020
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Thrombin-Binding Antibody Molecules And Uses Thereof
    Publication number: 20190276558
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Application
    Filed: March 25, 2019
    Publication date: September 12, 2019
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Thrombin-binding antibody molecules and uses thereof
    Patent number: 10370454
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: August 6, 2019
    Assignee: JANSSEN PHARMACEUTICALS, INC.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Modified serpins for the treatment of bleeding disorders
    Patent number: 10351619
    Abstract: This invention relates pro-coagulant serpin molecules engineered by modification of the P4, P2, P1 and/or P1? residues within the reactive center loop (RCL) to display increased specificity for anticoagulant proteases. These modified serpin molecules may be useful in therapy, for example as pro-coagulants for the treatment of bleeding.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: July 16, 2019
    Assignee: Cambridge Enterprise Limited
    Inventors: James Andrew Huntington, Stéphanie Polderdijk, Trevor Baglin
  • Thrombin-binding antibody molecules and uses thereof
    Patent number: 10287363
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: May 14, 2019
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Thrombin-Binding Antibody Molecules And Uses Thereof
    Publication number: 20180334511
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Application
    Filed: May 10, 2018
    Publication date: November 22, 2018
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Thrombin-Binding Antibody Molecules And Uses Thereof
    Publication number: 20180334512
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Application
    Filed: May 10, 2018
    Publication date: November 22, 2018
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • MODIFIED SERPINS FOR THE TREATMENT OF BLEEDING DISORDERS
    Publication number: 20180273610
    Abstract: This invention relates pro-coagulant serpin molecules engineered by modification of the P4, P2, P1 and/or P1? residues within the reactive center loop (RCL) to display increased specificity for anticoagulant proteases. These modified serpin molecules may be useful in therapy, for example as pro-coagulants for the treatment of bleeding.
    Type: Application
    Filed: May 4, 2018
    Publication date: September 27, 2018
    Inventors: James Andrew Huntington, Stéphanie Polderdijk, Trevor Baglin
  • Thrombin-binding antibody molecules and uses thereof
    Patent number: 9988463
    Abstract: This invention relates to isolated antibodies which recognise the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: June 5, 2018
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Thrombin-binding antibody molecules and uses thereof
    Patent number: 9988461
    Abstract: This invention relates to isolated antibodies which recognise the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: June 5, 2018
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown